Immune‐related hepatobiliary adverse events associated with mogamulizumab: A case series and literature review
Open Access
- 17 November 2026
- journal article
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Abstract
Summary: Mogamulizumab is a monoclonal antibody targeting CC‐chemokine receptor‐4 that is approved as a second‐line therapy for mycosis fungoides and Sézary syndrome. The most common adverse events include infusion‐related reactions and mogamulizumab‐associated rash. Conversely, solid organ involvement in immune‐related adverse events has been limited to sporadic reports. Regarding mogamulizumab, hepatobiliary complications appear to occur predominantly alongside the reactivation of viral hepatitis. As management differs substantially from that of infectious hepatitis and immune‐mediated adverse events involving solid organs are potentially life‐threatening, their early recognition and attribution to mogamulizumab therapy are of high clinical importance. Treatment depends on severity, and interruption of therapy may be required. We report five cases of non‐infectious hepatobiliary adverse events during mogamulizumab treatment and summarize the current state of the literature. The aim is to emphasize the importance of early recognition of immune‐mediated toxicities affecting solid organs during mogamulizumab therapy in the management of patients with cutaneous lymphomas.This publication has 20 references indexed in Scilit:
- Pharmacovigilance study for the identification of mogamulizumab-induced immune-related adverse events using a real-world databaseThe Oncologist, 2025
- Mogamulizumab‐Associated Autoimmune Diseases: Insights From FAERS Database AnalysisCancer Medicine, 2024
- Potential mogamulizumab-associated inflammatory bowel disease in cutaneous T-cell lymphoma managementJAAD Case Reports, 2024
- Immune-related adverse events associated with mogamulizumab: a comprehensive review of the literatureExpert Review of Anticancer Therapy, 2024
- Mogamulizumab-induced colitisEuropean Journal of Cancer, 2023
- Characterizing Outcomes in Visceral Cutaneous T-Cell Lymphoma: A Single Center Retrospective StudyClinical Lymphoma Myeloma and Leukemia, 2023
- Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapiesClinical Microbiology and Infection, 2022
- Risk of hepatitis B reactivation and cytomegalovirus related infections with Mogamulizumab: A retrospective study of international pharmacovigilance databaseeClinicalMedicine, 2020
- Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trialThe Lancet Oncology, 2018
- Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia–lymphoma patients with resolved HBV infection following systemic chemotherapyInternational Journal of Hematology, 2015